Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus.
EMS
270 participants
Nov 18, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Madalena association coated tablet.
Metformin 1000 mg extended-release tablet.
Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
Madalena association placebo tablet.
Metformin placebo tablet.
Empagliflozin + linagliptin placebo tablet.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04670666